Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial

pemvidutide (ALT-801) - Altimmune

https://events-distribution.easl.eu/from.storage?image=X9WvFraREucXDOc3lNmAYC1RBHYOoACgx4mbBO2KxZD9zl71r3wqCRskQuW4fqy80

Naim Alkhouri1,2; Shaheen Tomah3; Julio Gutierrez3,4; John Suschak3; Yukti Choudhury5; Elaine Chng5; Jay Yang3; M. Scot Roberts3; Rachel Garner3; Sarah Browne3; M. Scott Harris3; Christophe Arbet-Engels3; Mazen Noureddin1,6,7

Apr 19, 2026